Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | THRB | P10828 | 2/20 | 0.54 |
| ▸ | KDM6B | O15054 | 1/20 | 0.54 |
| ▸ | KDM4A | O75164 | 1/20 | 0.54 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.54 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | GABRP | O00591 | 5/20 | 0.41 |
| ▸ | GABRD | O14764 | 5/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 5/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 5/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29952027 | 1.00 | KMT2A (0.54) | KMT2AKDM4EMEN1TDP1ALDH1A1 | |
| SCHEMBL70537 | 0.81 | HCAR2 (0.46) | KMT2AKDM4EMEN1TDP1ALDH1A1 | |
| SCHEMBL16702890 | 0.78 | SMN1; SMN2 (0.38) | KMT2AKDM4EMEN1TDP1ALDH1A1 | |
| SCHEMBL29433274 | 0.73 | KDM4E (0.59) | KDM4EALDH1A1MAPTPOLBGLA | |
| SCHEMBL18065767 | 0.72 | KDM4E (0.31) | KMT2AKDM4EMEN1TDP1ALDH1A1 | |
| SCHEMBL3523197 | 0.72 | ALDH1A1 (0.42) | KMT2AKDM4EMEN1TDP1ALDH1A1 | |
| SCHEMBL353823 | 0.70 | GABRP (0.50) | KMT2AKDM4EALDH1A1GABRPGABRD | |
| SCHEMBL29952809 | 0.70 | GABRP (0.50) | KMT2AKDM4EALDH1A1GABRPGABRD | |
| SCHEMBL8828486 | 0.70 | ALDH1A1 (0.44) | KMT2AKDM4EMEN1TDP1ALDH1A1 | |
| SCHEMBL11398163 | 0.70 | KDM4E (0.39) | KMT2AKDM4EMEN1TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS LTD (GB) | 2023-11-09 | — | — | US | disclosed |
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS LTD (GB) | 2023-11-09 | — | — | US | disclosed |
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS LTD (GB) | 2023-11-09 | — | — | US | disclosed |
| EP-4214189-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL Business Ltd (GB) | 2023-07-26 | — | — | EP | disclosed |
| WO-2022058733-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS PLC (GB) | 2022-03-24 | — | — | WO | disclosed |
| EP-3354640-A2 | MIF INHIBITORS AND THEIR USES | Innovimmune Biotherapeutics, Inc. (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-2696682-B1 | MIF INHIBITORS AND THEIR USES | INNOVIMMUNE BIOTHERAPEUTICS INC (US) | 2018-03-21 | — | — | EP | disclosed |
| WO-2015155306-A1 | NEW TRPA1 ANTAGONISTS | ALMIRALL, S.A. (ES) | 2015-10-15 | — | — | WO | disclosed |
| US-9133164-B2 | MIF inhibitors and their uses | INNOV88 LLC (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133164-B2 | MIF inhibitors and their uses | INNOV88 LLC (US) | 2015-09-15 | — | — | US | disclosed |
| US-7038048-B2 | 3H-pyridopyrimidin-4-one compounds, compositions, and methods of their use | CYTOKINETICS, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| CN-1732168-A | Pyridodiazines as plant fungicides | SYNGENTA LTD (GB) | 2006-02-08 | — | — | CN | disclosed |
| EP-0900799-B1 | Novel atropisomers of 2,3-disubstituted-(5,6)-heteroarylfused-pyrimidin-4-ones | PFIZER PROD INC (US) | 2005-06-08 | — | — | EP | disclosed |
| EP-1513820-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20040116438-A1 | Compounds, compositions, and methods | CYTOKINETICS, INCORPORATED | 2004-06-17 | — | — | US | disclosed |
| WO-2003103575-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| US-6323208-B1 | COMPOUNDS TO TREAT NEURODEGENERATIVE, PSYCHOTROPIC DRUG AND ALCOHOL INDUCED CENTRAL AND INDUCED CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS. | PFIZER INC | 2001-11-27 | — | — | US | disclosed |
| US-5962457-A | NERVOUS SYSTEM DISORDERS | PFIZER INC. (US) | 1999-10-05 | — | — | US | disclosed |
| EP-0900799-A1 | Novel atropisomers of 2,3-disubstituted-(5,6)-heteroarylfused-pyrimidin-4-ones | Pfizer Products Inc. (US) | 1999-03-10 | — | — | EP | disclosed |
| EP-0807633-A2 | Novel 2,3-disubstituted-(5,6)- heteroarylfused-pyrimidine-4-ones | PFIZER INC. (US) | 1997-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | TTR, C1R, APOB | KMT2A 4615/4885KDM4E 4178/4885MEN1 2876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.